|
Age, n = 1561
|
| Median (IQR) |
40 (30–53) |
40 (28.8–52) |
47 (35–56.2) |
40 (31–52) |
|
Age group, n = 1561
|
| <20, n (%) |
16 (1) |
15 (1) |
1 (<1) |
0 (0) |
| 20–29, n (%) |
373 (24) |
335 (26) |
31 (14) |
7 (19) |
| 30–39, n (%) |
343 (22) |
291 (22) |
42 (19) |
10 (27) |
| 40–49, n (%) |
330 (21) |
270 (21) |
51 (23) |
9 (24) |
| 50–59, n (%) |
314 (20) |
248 (19) |
60 (27) |
6 (16) |
| 60+, n (%) |
185 (12) |
141 (11) |
39 (17) |
5 (14) |
|
Sex, n = 1561
|
| female, n (%) |
1318 (84) |
1105 (85) |
189 (84) |
24 (65) |
| male, n (%) |
243 (16) |
195 (15) |
35 (16) |
13 (35) |
|
Hospital, n = 1561
|
| Acad. K Central University Hosp., n (%) |
300 (19) |
240 (18) |
49 (22) |
11 (30) |
| Batumi Republican Hospital, n (%) |
276 (18) |
216 (17) |
52 (23) |
8 (22) |
| Bochorishvili Clinic, n (%) |
194 (12) |
178 (14) |
14 (6) |
2 (5) |
| Bokeria Tbilisi Referral Hospital, n (%) |
309 (20) |
266 (20) |
37 (17) |
6 (16) |
| Caucasus Medical Centre, n (%) |
299 (19) |
251 (19) |
40 (18) |
8 (22) |
| Infectious Disease Hospital, n (%) |
183 (12) |
149 (11) |
32 (14) |
2 (5) |
|
Occupation/Role in hospital, n = 1561
|
| Nurse or Midwife, n (%) |
604 (39) |
537 (41) |
58 (26) |
9 (24) |
| Medical Doctor, n (%) |
306 (20) |
181 (14) |
108 (48) |
17 (46) |
| Other, n (%) |
651 (42) |
582 (45) |
58 (26) |
11 (30) |
|
Household size, n = 1561
|
| 1–3, n (%) |
703 (45) |
579 (45) |
107 (48) |
17 (46) |
| 4–5, n (%) |
622 (40) |
526 (40) |
83 (37) |
13 (35) |
| 6+, n (%) |
236 (15) |
195 (15) |
34 (15) |
7 (19) |
|
Any chronic condition, n = 1561
|
| No, n (%) |
1171 (75) |
988 (76) |
155 (69) |
28 (76) |
| Yes, n (%) |
390 (25) |
312 (24) |
69 (31) |
9 (24) |
|
Number of chronic conditions, n = 1561
|
| 0, n (%) |
1171 (75) |
988 (76) |
155 (69) |
28 (76) |
| 1, n (%) |
307 (20) |
252 (19) |
48 (21) |
7 (19) |
| ≥2, n (%) |
83 (5) |
60 (5) |
21 (9) |
2 (5) |
|
Body mass index, n = 1561
|
| Underweight or normal, n (%) |
721 (46) |
607 (47) |
101 (45) |
13 (35) |
| Overweight, n (%) |
481 (31) |
394 (30) |
74 (33) |
13 (35) |
| Obese, n (%) |
359 (23) |
299 (23) |
49 (22) |
11 (30) |
|
Smoking, n = 1560
|
| Currently smokes, n (%) |
388 (25) |
323 (25) |
48 (21) |
17 (46) |
| Never smokes, n (%) |
1030 (66) |
865 (67) |
148 (66) |
17 (46) |
| Previously smokes, n (%) |
142 (9) |
111 (9) |
28 (12) |
3 (8) |
|
Self-assessed health status, n = 1561
|
| Excellent, n (%) |
127 (8) |
104 (8) |
17 (8) |
6 (16) |
| Very good, n (%) |
252 (16) |
206 (16) |
37 (17) |
9 (24) |
| Good, n (%) |
521 (33) |
438 (34) |
68 (30) |
15 (41) |
| Fair, n (%) |
641 (41) |
533 (41) |
101 (45) |
7 (19) |
| Poor, n (%) |
20 (1) |
19 (1) |
1 (<1) |
0 (0) |
|
Hands on care, n = 1561
|
| No, n (%) |
745 (48) |
639 (49) |
91 (41) |
15 (41) |
| Yes, n (%) |
816 (52) |
661 (51) |
133 (59) |
22 (59) |
|
Received influenza vaccine during 2020–2021 influenza season, n = 1561
|
| No, n (%) |
1068 (68) |
944 (73) |
105 (47) |
19 (51) |
| Yes, n (%) |
492 (32) |
355 (27) |
119 (53) |
18 (49) |
|
Face-to-face patient contact, n = 1561
|
| No, n (%) |
336 (22) |
292(22) |
37 (17) |
7 (19) |
| Yes, n (%) |
1125 (78) |
1008 (78) |
187 (81) |
30 (81) |
|
Previous SARS-CoV-2 infection (before enrollment) confirmed by PCR or RAT, n = 1561
|
| 0, n (%) |
814 (52) |
645 (50) |
136 (61) |
33 (89) |
| 1, n (%) |
747 (48) |
655 (50) |
88 (39) |
4 (11) |
|
Previous SARS-CoV-2 infection (before enrollment) confirmed by any test: PCR, RAT or serology, n = 1561
|
| 0, n (%) |
558 (36) |
437 (34) |
120 (54) |
1 (3) |
| 1, n (%) |
1003 (64) |
863 (66) |
104 (46) |
36 (97) |
|
Seropositive at enrolment (AntiS+ or AntiN+), n = 1555
|
| 0, n (%) |
569 (37) |
446 (34) |
122 (55) |
1 (3) |
| 1, n (%) |
986 (63) |
850 (66) |
100 (45) |
36 (97) |
|
Anti-S+, n = 1558
|
| 0, n (%) |
589 (38) |
460 (35) |
124 (56) |
5 (14) |
| 1, n (%) |
969 (62) |
838 (65) |
99 (44) |
32 (86) |
|
Anti-N+, n = 1552
|
| 0, n (%) |
639 (41) |
502 (39) |
130 (59) |
7 (19) |
| 1, n (%) |
913 (59) |
791 (61) |
92 (41) |
30 (81) |
|
Delay between first dose and start of person-time contribution, in days (n = 261)
|
| Median (IQR) |
2 (1–4) |
_ |
2 (1–3) |
30 (29–31) |
|
Delay between second dose and start of person-time contribution, in days (n = 37)
|
| )Median (IQR) |
7 (3–9) |
_ |
_ |
7 (3–9) |
|
COVID-19 Vaccine product received prior to start of person-time contribution, n = 1561
|
| Unvaccinated, n (%) |
1300 (83) |
1300 (100) |
0 (0) |
0 (0) |
| ChAdOx1-S—2 doses, n (%) |
3 (<1) |
0 (0) |
0 (0) |
3 (8) |
| BNT162b2—1 dose, n (%) |
145 (9) |
0 (0) |
145 (65) |
0 (0) |
| BNT162b2—2 dose, n (%) |
26 (2) |
0 (0) |
0 (0) |
26 (70) |
| BBIBP-CorV—1 dose, n (%) |
33 (2) |
0 (0) |
33 (15) |
0 (0) |
| BBIBP-CorV—2 dose, n (%) |
4 (<1) |
0 (0) |
0 (0) |
4 (11) |
| CoronaVac—1 dose, n (%) |
28 (2) |
0 (0) |
28 (12) |
0 (0) |
| CoronaVac—2 doses, n (%) |
4 (<1) |
0 (0) |
0 (0) |
4 (11) |
